Axsome Q2 Revenue Misses Expectations Despite Auvelity Growth

Axsome Therapeutics reported second-quarter net product revenues of $218.4 million, a 45.2% increase from the prior year but below the Zacks Consensus Estimate of $225 million. The company incurred a loss of 99 cents per share, aligning with analyst expectations and slightly widening the previous year's loss of 97 cents per share. This performance marks a slight underperformance relative to the broader market, with shares declining 3.7% in the month following the report.

The revenue shortfall was driven primarily by weak results from the company's newest asset, Symbravo, which sold $2.3 million worth of product against a consensus estimate of $7.2 million. Conversely, the core business remained robust, with Auvelity generating $180.3 million in sales, a 51% year-over-year jump that exceeded market forecasts. Sunosi contributed $35.8 million in net product sales, also outperforming the estimated $33.4 million. According to GN markets/earnings (en-US), these figures reflect the current state of the company's portfolio before any forward-looking projections are considered.

Auvelity Drives Prescription Volume Growth

Auvelity remains the primary engine for Axsome's top line, accounting for the majority of the $216.4 million in net product revenues. The company recorded approximately 266,000 prescriptions for the drug in the second quarter, representing a 34% increase over the same period last year. This volume growth supports the 51% sales expansion, indicating that the increase is driven by both higher adoption and pricing stability rather than volume declines.

Sunosi also demonstrated consistent momentum, with United States prescriptions rising 14% year-over-year to 61,000. This operational metric underpinned the 20% sales growth for the drug. While these two established products delivered results above consensus, their combined strength was insufficient to offset the initial sales stumble of the newly launched Symbravo, resulting in the overall revenue miss.

Symbravo Launch Shows Mixed Initial Traction

Symbravo, launched in the United States in June 2025, generated $2.3 million in second-quarter sales, a decline from $4.1 million in the prior quarter. This figure missed the consensus estimate of $7.2 million, highlighting a gap between expected and actual commercial uptake during this specific period. Despite the revenue miss, the company reported 23,500 total prescriptions, which represents a 30% sequential increase, suggesting that prescription volume is still building even as immediate revenue recognition lags.

Research Costs Decline Amid Portfolio Shift

Research and development expenses totaled $46.2 million, a 6.7% decrease from the year-ago quarter. The reduction was attributed to lower costs associated with Auvelity and the AXS-14 program. This operational efficiency partially offset the revenue miss, allowing the per-share loss to remain in line with estimates rather than widening significantly. The company’s financial structure continues to rely on the scaling of its marketed drugs to fund ongoing development efforts, with royalty and milestone revenues contributing a modest $2 million from Sunosi’s out-licensed territories.